MedTrace Logo

Biological, Radiographic and Clinical Evaluation of Various Inter-Visit Root Canal Dressings in Retreatment Cases

NCT07641933 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-06-12

No results posted yet for this study

Summary

The aim of this clinical trial is to evaluate anti-inflammatory effect of various intracanal medications:

1. Calcium Hydroxide Slurry mixed with 3% Sodium Hypochlorite
2. Calcium Silicate
3. Calcium Hydroxide

In retreatment cases in terms of:

1. Biological Evaluation: Biomarker (IL 1B)
2. Radiographic Evaluation: CBCT
3. Clinical Evaluation: Pain Score (VAS)

Conditions

  • Intervention Studies
  • ASA Physical Status I
  • Intracanal Medication
  • Periapical Abscess
  • Retreatment

Interventions

DRUG

Calcium Silicate Intracanal Medication

Calcium silicate-based bioceramic materials have gained attention for their bioactivity and biocompatibility, acting through hydration with calcium hydroxide release followed by hydroxyapatite formation that promotes healing. Bio-C Temp is an example, characterized by high calcium ion release, alkaline pH, adequate radiopacity, and good biocompatibility.

DRUG

Calcium Hydroxide Slurry mixed with Sodium Hypochlorite Intracanal Medication

Combining calcium hydroxide with sodium hypochlorite (NaOCl) has been proposed. NaOCl provides rapid and potent antimicrobial and tissue-dissolving effects, while Ca(OH)₂ offers prolonged action. Both agents retain their properties when combined, and this combination may produce a synergistic effect that enhances disinfection and reduces chair time in two-visit treatment protocols.

DRUG

Calcium Hydroxide (Ca(OH)2) Intracanal Medication

Calcium hydroxide ICM being the most widely used due to its high alkalinity, antimicrobial properties, endotoxin neutralization, and ability to reduce periapical inflammation. It is applied as an aqueous mixture or polyethylene glycol-based paste and provides a slow but sustained antimicrobial effect. Despite their benefits, Ca(OH)₂ medicaments re limited by their solubility, susceptibility to tissue fluids, potential to weaken tooth structure over time, and reduced effectiveness against resistant microorganisms such as Candida Albicans and Enterococcus Faecalis.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-06-30
Completion
2027-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07641933 on ClinicalTrials.gov